2025-12-04 - Analysis Report
Okay, here's a breakdown of the TEM (Tempus AI Inc.) stock performance and analysis based on the provided data:

**0) Summary of Key Data Points**

*   **Cumulative Return (TEM):** 33.32%
*   **Cumulative Return (VOO/S&P 500):** 29.80%
*   **Divergence from S&P 500:** 9.8 (Relative Divergence: 43.8)
*   **Recent Price:** $74.69
*   **5-day SMA:** $76.37
*   **20-day SMA:** $72.75
*   **60-day SMA:** $82.84
*   **MRI:** 0.9 (High Investment Recommended)
*   **RSI:** 55.62
*   **PPO:** 1.50
*   **Analyst Consensus:** Buy (Mean Rating: 2.14)
*   **Average Target Price:** $91.42

**1) Return Rate Comparison (TEM vs. S&P 500)**

*   **Company Overview:** Tempus AI Inc. is a technology company focused on precision medicine through data and artificial intelligence.
*   **Performance:** TEM has outperformed the S&P 500 over the tracked period.
*   **Divergence:** The current divergence of 9.8 indicates that TEM's cumulative return exceeds that of the S&P 500 by 9.8 percentage points at the end of the data. The relative divergence of 43.8 suggests that the current level of outperformance is near the middle of its historical range relative to the S&P 500.

    **Alpha, Beta Analysis:**

    *   **CAGR (2023-2025):** 33.0% indicates substantial growth over this period.
    *   **MDD (2023-2025):** 76.7% suggests high volatility.
    *   **Alpha:** 5.0% indicates that TEM has generated returns exceeding what would be expected based on its beta (market risk).
    *   **Beta:** 0.3 suggests that the stock is significantly less volatile than the market overall.
    *   **Cap(B):** 13.3 This represents the market capitalization of the company in billions of dollars.

**2) Recent Stock Price Fluctuations**

*   **Closing Price:** The most recent closing price is $74.69.
*   **Recent Market Activity:** The stock showed a slight increase in the last market session.
*   **Moving Averages:**  The 5-day SMA is above the 20-day SMA, which is a bullish signal. However, the 60-day SMA is significantly higher than both, indicating a potential downtrend in the longer term.

**3) Technical Indicators & Signals**

*   **Market Risk Indicator (MRI):** An MRI of 0.9 indicates a "High Investment Recommended" level of risk according to the provided scale.
*   **RSI:** An RSI of 55.62 is neutral, suggesting neither overbought nor oversold conditions.
*   **PPO:** The PPO of 1.4964 suggests that the short-term moving average is slightly above the long-term moving average, which can be considered a mildly bullish signal.
*   **Hybrid Signal:** The "cash_0%_Buy 100% of cash" signal recommends investing all available cash in TEM, indicating a strong buy signal based on the model.
*   **Recent Divergence Change:** A recent 20-day relative divergence change of -2.9 indicates a short-term downward trend in TEM's performance relative to the S&P 500.
*   **Expected Return:** The "nan" value for Expected Return likely means the data is unavailable or cannot be reliably calculated.

**4) Recent News & Significant Events**

*   **FDA Clearance & Earnings Report:** News suggests focus on FDA clearance and earnings reports.
*   **Earnings Surge & Partnership:** News suggests focus on earnings surge and research partnership.
*   **Analyst Opinions:** Reports cover whether to buy, hold, or sell TEM stock after Q3 earnings.
*   **Institutional Investment:** Riverview Capital Advisers LLC increased its stake in Tempus AI, indicating confidence from at least one institutional investor.

**4-2) Analyst Opinions**

*   **Consensus:** The analyst consensus is "Buy" with an average rating of 2.14, leaning towards a buy recommendation.
*   **Target Price:** The average target price is $91.42, indicating a potential upside from the current price.
*   **Recent Changes:** No changes were shown with the "â†’ ()", indicating that the data is either missing or there were no changes.

**5) Comprehensive Analysis**

Tempus AI (TEM) has outperformed the S&P 500 over the period analyzed, but recent data suggest that the stock may be weakening relative to the index. The company exhibits high volatility but with a beta under 1. Recent news highlights positive developments such as FDA clearance considerations, earnings surges, and new partnerships, and an increased stake by Riverview Capital Advisers LLC. However, some articles focus on whether the stock is a "buy, hold, or sell," indicating potential uncertainty among analysts.

Technically, the short-term moving averages are favorable, and the high MRI suggests the model considers it a good investment opportunity. Analyst consensus is also strongly in the "Buy" territory with a significant upside potential based on the average target price.

**Overall Recommendation:**

While the recent short-term divergence is slightly negative, TEM appears to be a potentially attractive investment based on a combination of factors: positive analyst sentiment, recent news events (partnership, earnings surge), high returns relative to the market and high MRI suggesting high investment potential. However, investors should be aware of the stock's high volatility and conduct thorough research before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.